Do not reuse a shortage-era supplier assessment or a 2025 programme-price spreadsheet without updating it. The following developments materially affect the procurement questions to ask.
| Verified development | Procurement implication |
|---|---|
| FDA's GLP-1 clarification states that semaglutide and tirzepatide are not on the 503B bulks list or its drug-shortage list; the retrieved shortage index does not list their injections as currently in shortage. | Do not treat historical shortage arrangements as the default basis for new commitments. Check the exact product and status again before contracting. (fda.gov) |
| The Fifth Circuit affirmed the judgments supporting FDA's tirzepatide and semaglutide shortage decisions on August 27, 2026; the retrieved semaglutide opinion was revised September 1, 2026. | A statement that litigation automatically preserves shortage-era supply requires current, case-specific evidence. These opinions do not replace assessment of individual compounding arrangements. (govinfo.gov) |
| FDA announced a proposal on April 30, 2026 not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. | Distinguish the proposal from existing restrictions. A final determination was not verified in the official material retrieved for this report; do not describe the proposal itself as a final rule. (fda.gov) |
| California introduced additional nonresident-pharmacy requirements effective July 1, 2026, including designation of a California-licensed pharmacist-in-charge for California operations. | Refresh destination-state evidence rather than relying on an old national-coverage spreadsheet. (pharmacy.ca.gov) |
| FDA's current DSCSA page extends specified exemptions for qualifying small dispensers to November 27, 2027. | Do not use an obsolete blanket November 2026 deadline. Determine the entity's role, eligibility and the specific requirements covered. (fda.gov) |
| FDA announced GLP-1 safety-labelling changes on November 9, 2026, concerning a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a rare serious eye condition. | Require clinical leadership and partners to maintain current counselling, safety communications and escalation procedures. This is not a procurement-led reason to switch treatment. (fda.gov) |
Outstanding legal verification: This review located the appellate opinions and FDA materials above, but did not establish a complete subsequent litigation docket or every later administrative action. Obtain a dated, product-specific legal assessment before relying on a disputed supply theory.
Explore the table row by row
A working view of the research
FDA's GLP-1 clarification states that semaglutide and tirzepatide are not on the 503B bulks list or its drug-shortage list; the retrieved shortage index does not list their injections as currently in shortage.
- Procurement implication
- Do not treat historical shortage arrangements as the default basis for new commitments. Check the exact product and status again before contracting. (fda.gov)
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- govinfo.gov · Source 2 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
- fda.gov · Source 3 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list?utm_source=openai
- pharmacy.ca.gov · Source 4 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
- fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- fda.gov · Source 6 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential?trk=public_post_comment-text